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1. Introduction 
Despite significant advances in the modern diagnosis and pharmacologic and 
nonpharmacologic therapy for heart failure, with a reduction of mortality of more than 50%, 
long-term prognosis of the disease still is poor and, often, with uncertain outcome [1, 2]. 
The great expectations set in vasopeptidase inhibitors, tumor necrosis factor–┙ antagonists, 
metalloproteinase inhibitors, endothelin antagonists, and adenosine A1-receptor antagonists 
could not be verified by findings as has been shown in large-scale clinical trials. The calcium 
sensitizer levosimendan, the vasopressin V2-receptor antagonist tolvaptan, and the 
natriuretic peptide (NP) nesiritide only partially fulfilled the expectations. There remains an 
urgent unmet need for new therapies with new drugs and new modes of action. 
Drugs that modulate soluble guanylate cyclase (sGC) and cyclic guanosine 3’, 5’-
monophosphate (cGMP) levels are emerging as promising therapies for heart failure. The 
sGC activator cinaciguat and sGC stimulators riociguat and BAY 60-4552 as modulators of 
sGC are promising drugs with favorable effects such as vasodilatation; inodilation; and 
antiproliferative, antiapoptotic, and antiremodeling effects through protein kinase G-type 
and phosphodiesterases as well as calcium ion channels [3]. 
Cinaciguat (BAY 58-2667) is a novel molecule that activates regulatory sites on both the ┙ 
and ┚ subunits of sGC, a key signal transduction enzyme that synthesizes cGMP in response 
to binding of nitric oxide. Cinaciguat has a unique feature, to activate sGC independently of 
NO and of the prosthetic heme group. Cinaciguat is even more potent if the heme group is 
oxidized and insensitive to NO.  
Riociguat (BAY 63-2521) is a direct stimulator of sGC in vitro and in vivo that is 
independent from NO, the endogenous activator of the enzyme. Moreover, in the presence 
of NO, it enhances the effect of NO [4, 5]. In previous clinical studies, riociguat revealed 
beneficial effects and good tolerability in patients with pulmonary hypertension [6] and 
patients with severe heart failure [7]. 
This article summarizes the pathophysiologic relevance and therapeutic potential of the 
sGC–cGMP signalling system in acute and chronic heart failure. 
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2. Guanylate cyclase pathway 
Cyclic guanosine 3’, 5’-monophosphate is a second messenger that plays a role in various 
crucial physiologic pathways, including cardiovascular homeostasis, cellular growth and 
contractility, inflammation, sensory transduction, and neuronal plasticity and learning [8]. 
Guanylate cyclases (GC) are enzymes that catalyze the conversion of guanosine-5'-
triphosphate to cGMP. The GC-family includes both membrane-bound and soluble isoforms 
that are expressed in nearly all cell types. Membrane-bound particulate guanylate cyclase 
(pGC) serves as a receptor for NPs, whereas plasmatic sGC acts as a receptor for biological 
messenger NO. Subsequently, cGMP effectors include cGMP-dependent protein kinases, 
cGMP-regulated phosphodiesterases, and cyclic nucleotide-gated ion channels (Fig. 1) [9]. 
 
NO—nitric oxide; NP—natriuretic peptide; RTK; pGC—particulate guanylate cylase; sGC—soluble 
guanylate cyclase; cGMP—cyclic guanosine 3’, 5’-monophosphate; PDEs—phosphodiesterases; cGKs—
cGMP-dependent protein kinases; GTP—guanosine-5'-triphosphate; PAK; GDP; IRAG—inositol 1,4,5-
trisphosphate receptor I–associated protein; cAMP—cyclic adenosine monophosphate. 
Fig. 1. sGC– and pGC–cGMP signalling pathways. cGMP acts through cGMP effectors 
including cGMP-dependent protein kinases, cGMP-modulated cation channels, and cGMP-
regulated phosphodiesterases that hydrolyze cyclic nucleotides. 
Both the NO–sGC–cGMP pathway and the NP–pGC–cGMP pathway are disordered in a 
range of cardiovascular conditions, including acute decompensated heart failure (ADHF) 
[10]. 
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The NP–pGC signalling pathway has been shown to play an important role as a 
compensatory mechanism that reduces neurohumoral activation in heart failure. pGC 
contains an extracellular ligand-binding domain and an intracellular catalytic domain 
connected by a single transmembrane domain [11]. At least seven pGC family members 
have been identified and sequenced (GC-A to GC-G).  
In humans, NPs constitute a family of at least four identified members:  atrial natriuretic 
peptide (ANP) and B-type natriuretic peptide (BNP), of myocardial origin; C-type 
natriuretic peptide (CNP), derived from the endothelial cells; and urodilatin, produced in 
the kidneys [12, 13]. The GC-A binding ligands ANP and BNP are produced predominantly 
in the cardiac atria and ventricles and released in the circulation in response to 
hypervolemia, as seen, for example, in congestive heart failure, to regulate blood pressure 
and body fluid homeostasis. An activation of a GC-A binding domain by ANP and BNP 
results in cGMP increase mediating hypotensive and cardioprotective actions through 
increased natriuresis, inhibition of the renin-aldosterone pathway, as well as vasorelaxant, 
antifibrotic, antihypertrophic, and lusitropic effects [10, 13].  
In patients with heart failure, the described compensatory response to NPs is disturbed due 
to markedly altered distribution and degradation of the NPs [14]. It has been demonstrated 
that there is an inadequate neurohumoral response to volume/sodium overload not only in 
advanced stages of heart failure, but also in patients with only very mild symptoms of the 
disease [15]. 
As for the NO–sGC–cGMP pathway, in conditions of oxidative stress that typically occur 
with cardiovascular diseases, the NO production is reduced. On the other hand, the NO 
degradation and neutralization by oxidants such as superoxide is excessively increased, 
contributing to an overall NO deficiency [3, 16]. Additionally, the oxidation of the heme 
group on sGC impairs the enzyme bioavailability and responsiveness to endogenous NO 
and exogenous nitrovasodilators reducing the activation of this signalling pathway even 
further [3]. 
The described disruption of physiologic signalling response in patients with heart failure 
builds the rationale for new therapeutic agents that target these GC pathways.  
Several novel drugs that induce the pGC–cCMP pathway include NP analogues nesiritide 
and ularitide. Both compounds show natriuretic, diuretic, and vasodilating effects [17, 18]. 
While there is good evidence of positive short-term hemodynamic effects of nesiritide in 
ADHF [19], there still is controversy regarding its safety risks, including renal dysfunction 
and long-term mortality [20], that needs to be addressed in future trials. Ularitide currently 
is being evaluated and is showing promising effects on preserving renal function in patients 
with decompensated heart failure. These results also need to be further investigated in lager 
trials [21, 22]. 
Although the activation of sGC and pGC cascades produce the same second messenger, it 
has been demonstrated that the effects of cGMP differ in dependence of the origin of 
production. The probable explanation for this effect are different locations of GCs within the 
cardiac myocytes with sGC being mainly located in the cytosol and pGC being mainly 
found in subsarcolemmal areas [23]. This concept of compartmentalization of cGMP is 
particularly interesting for predicting effects of novel therapies modulating either one or the 
other signaling pathway. Thus, the effects of synthetic NP analogues like nesiritide or 
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ularitide as ligands of pGC differ slightly from therapeutic agents that target sGC like 
cinaciguat.  
In the following section, we focus on the cGC–cGMP pathway and its activation through a 
novel NO-independent activator cinaciguat (BAY 58-2667). 
3. sGC signalling pathway 
NO is a key signaling molecule in a variety of physiologic processes in mammals. NO is 
produced endogenously from the amino acid L-arginine by the enzyme NOS.  There are 
different NOS isoforms that were isolated from the brain, vascular endothelium, and 
macrophages [24]. Endothelial NOS (eNOS) is a Ca2+- and calmodulin-dependent NO-
synthase that originally was identified as constitutive in vascular endothelial cells. 
Activation of eNOS is induced by two basic pathways: sheering forces produced by blood 
flow and endothelial receptors for a variety of ligands like bradykinin, acetylcholine, 
adenosine, and other vasoactive substances. Both pathways cause a release of calcium with 
subsequent eNOS activation. eNOS produces nitric oxide and activates sGC located in the 
adjacent vascular smooth muscle cells, thereby increasing levels of cGMP and inducing 
vasorelaxation. This mechanism is thought to play a major role in the regulation of vascular 
tone and blood pressure [24].  
Reduced bioavailability and/or responsiveness to endogenous NO contribute to the 
development of cardiovascular diseases [3, 10]. Organic nitrates, such as nitroglycerin, 
and other NO-donor drugs, known as vasodilators, as they showed beneficial effects on a 
variety of cardiovascular diseases including various anginal syndromes and congestive 
heart failure. During short-term therapy, nitrates rapidly improve hemodynamics by 
increasing levels of cGMP in the vascular smooth muscle cell with resultant peripheral 
arteriolar and venous vasodilatation providing a decrease in filling pressures and systemic 
vascular resistance, and thereby lowering myocardial oxygen consumption [25]. However, 
one of the major limitations of nitrates is the development of dose-related tolerance in long-
term treatment, as well as nonspecific interactions of NO with other biological molecules [3, 
26]. Furthermore, despite potent short-term symptoms relief, there is no clear evidence of 
long-term mortality reduction in patients with cardiovascular disease [3]. 
To understand the difference between the mechanisms of actions of traditional therapeutics 
like nitrates and new compound like cinaciguat, it is important to outline the structure of 
their receptor sGC. sGC is a heterodimer consisting of an ┙- and a heme-containing ┚-
subunit. NO only can induce sGC upon binding to its reduced Fe2+ heme moiety. It its 
oxidized state, sGC heme strongly reduces its affinity for the sGC heme binding site, often 
resulting in a subsequent loss of the prosthetic heme group. Its loss renders the enzyme 
insensitive to endogenous and exogenous NO [3, 27, 28]. 
Cardiovascular diseases like atherosclerosis, diabetes, and hypertension are associated with 
a high degree of oxidative stress. During oxidative stress, reactive oxygen species (ROS) 
interfere with NO–sGC signalling pathway by reducing NO bioavailability and by oxidizing 
the sGC heme moiety, thereby leading to sGC degradation.  
Unlike conventional nitrovasodilators, two novel therapeutic groups can induce sGC in its 
NO-insensitive state, so-called sGC-activators and sGC-stimulators. sGC-activators like 
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cinaciguat induce the soluble guanylate cyclase in its NO-insensitive, oxidized ferric (Fe3+) 
heme-free state. On the other hand, sCG-stimulators like YC-1, BAY 41-2272, CFM-1571, A-
350619, and riociguat enhance the affinity of sGC to already very low levels of NO, thereby 
producing synergistic effects with NO (Fig. 2). 
 
NO—nitric oxide; GTP—guanosine-5'-triphosphate; sGC—soluble guanylate cyclase; PDEs—
phosphodiesterases; GMP—guanosine monophosphate; MMP; PARP; NOS—nitric oxide synthase. 
Fig. 2. NO–sGC–cGMP signalling pathway. Mechanism of action of sGC stimulators and 
sGC activators. See text for explanation. 
4. Cinaciguat: Clinical benefits in decompensated heart failure  
Cinaciguat, the first of a new class of sGC activator, is in early clinical development for the 
treatment of acute decompensated heart failure (ADHF). The few preclinical and clinical 
data show that it has great potential as an effective substance for treatment of ADHF. In 
animal experimental studies, the cardiorenal effects of intravenous cinaciguat 0.1 or 0.3 
g/kg/min were evaluated [29, 30]. Cinaciguat potently unloads the heart by reducing 
arterial pressure, pulmonary arterial pressure, and pulmonary capillary wedge pressure 
(PCWP), thereby increasing the cardiac output (CO), renal blood flow, and glomerular 
filtration rate. 
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Initial studies in healthy volunteers have demonstrated the clinical utility of cinaciguat. A 
favorable safety profile and efficacy were documented in lower doses of 50 to 250 µg/h for 
up to 4 hours [31]. 
After initial dose finding, cinaciguat was evaluated in a nonrandomized, uncontrolled, 
proof-of-concept study that included 33 patients with ADHF of functional classes NYHA III 
and IV and PCWP of 18 mm Hg or greater using a starting dose of 100 µg/h, which could be 
uptitrated to final doses of 50 to 400 ng/h depending on hemodynamic response. 
Patients were categorized as responders to the new substance if the PCWP decreased by 4 
mm Hg or more compared with baseline. The responder rate was 53% after 2 hours, 83% 
after 4 hours, and 90% after 6 hours. The proportion of patients reporting improvements 
in dyspnea scores increased during and after 6 hours of cinaciguat intravenous infusion 
[32, 34]. 
Initial results showed promising evidence of the therapeutic potential and safety of 
cinaciguat: continuous intravenous administration was well tolerated and increased the 
potent venous and arterial dilation, which led to significant cardiac preload and afterload 
reduction and increased cardiac index. Compared with baseline, a 6-hour infusion of 
cinaciguat led to significant reductions in mean pulmonary artery pressure (–6.5 mm Hg), 
PCWP (7–8 mm Hg), mean right arterial pressure (–2.9 mm Hg), PVR (–43.4 dynes/s/cm-5), 
and SVR (–597 dynes/s/cm-5), while increasing heart rate by 4.4 bpm and CO by 1.68 L/min 
[33, 34]. 
Of 60 patients, 13 reported 14 drug-related treatment-emergent adverse events of mild to 
moderate intensity, most commonly hypotension.  
In a placebo-controlled, randomized, double-blind, multicenter, international phase 2b 
study, the safety and efficacy of intravenous cinaciguat as an add-on to standard therapy 
was investigated in 159 patients with ADHF. Hemodynamic effects were monitored via 
Swan-Ganz thermodilution catheter (Edwards Lifesciences, Irvine, CA) in patients with 
NYHA functional class III and IV HF and PCWP of 18 mm Hg or greater [35]. 
Cinaciguat dose was titrated from 100 to a maximum of 600 µg/h for the first 8 hours and 
was then maintained for up to 40 hours. Primary end point was a change in PCWP after 8 
hours compared with placebo; secondary end points included hemodynamic and safety 
parameters, organ protection, and 30-day mortality. 
In this study, 159 patients on stable standard therapy were enrolled within 48 hours after 
hospital admission to receive placebo or cinaciguat. The new substance caused a rapid and 
sustained decrease in the primary end point PCWP, increased CO, and decreased 
pulmonary vascular resistance (PVR) without changing heart rate. No adverse effects on 
cardial or renal function or 30-day mortality were observed despite increased occurrence of 
several cases of oligosymptomatic hypotension at high doses of cinaciguat, which led to 
prematurely termination of the study [35]. 
Under low dosage of intravenous Cinaciguat, a phase 2b study (COMPOSE EARLY) 
currently is recruiting participants to investigate the efficacy and tolerability of Cinaciguat 
(150 µg/h, 100 µg/h, 50 µg/h) [35]. The results are expected within the next 2 years. 
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5. Riociguat: Clinical utility in heart failure and pulmonary hypertension 
Riociguat has shown its unique mechanism of action through simultaneous lowering systemic 
vascular resistance (SVR) and PVR in a phase 2 trial in patients with pulmonary arterial 
hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTEPH) [6]. 
The trials confirmed the expected pharmacologic mode of action, which is consistent with 
the properties of a sGC stimulator and showed significant effects on pulmonary 
hemodynamics (decrease of PVR, increase of CO), echocardiographic parameters, N-
terminal proBNP levels, and functional capacity (improvement in 6-minute walking 
distance) without major safety concerns. Improvements also were observed in NYHA 
functional class and Borg dyspnea score. Riociguat was well tolerated and had a favorable 
safety profile [6, 31]. 
Based on these data, two randomized, placebo-controlled, phase 3 studies have begun: the 
CHEST-1 study (A Study to Evaluate Efficacy and Safety of Oral BAY63-2521 in Patients 
With CTEPH) in patients with CTEPH and the PATENT-1 trial (A Study to Evaluate 
Efficacy and Safety of Oral BAY63-2521 in Patients With Pulmonary Arterial Hypertension) 
for patients with PAH. Both studies will be followed by open long-term studies (CHEST-2 
and PATENT-2). Recruitment for CHEST-1 and PATENT-1 is ongoing. Results from the 
study program are expected in 2011. 
Similar reduction of SVR and PVR was seen in a single-dose study in 42 patients with 
biventricular heart failure (LVEF < 45%, pulmonary artery pressure mean > 25 mm Hg, and 
PCWP > 18 mm Hg) to evaluate the acute hemodynamic response to BAY 60-4552, a main 
metabolite of riociguat. Oral administration of doses from 1 to 10 mg was well tolerated and 
mediated a potent vasodilation. Biventricular preload and afterload were improved, 
subsequently resulting in a significant increase of cardiac index. Riociguat shows great 
promise for treatment in pulmonary hypertension associated with left ventricular systolic 
dysfunction on top of standard congestive heart failure therapy. 
Currently, riociguat is being investigated in a multicenter study in patients with congestive 
heart failure and pulmonary hypertension (LEPHT study [A Study to Test the Effects of 
Riociguat in Patients With Pulmonary Hypertension Associated With Left Ventricular 
Systolic Dysfunction]). 
6. Conclusions 
Cyclic guanosine-3’,5’ monophosphate is a second messenger that plays a role in various 
physiologic signalling pathways. It is produced either by membrane-bound pGC or sGC. 
pGC is induced by NPs; sGC by NO. In cardiovascular diseases like ADHF, the 
physiological NO–sGC and NP–pGC signalling pathways are disrupted. 
Cinaciguat, a novel NO-independent sGC activator, offers many advantages over traditional 
organic nitrates and other NO-donor drugs, whose use often is limited due to tolerance 
development, limited biometabolism, nonspecific interactions, lack of sGC activation in the 
absence of the sGC heme moiety, and lack of benefit in long-term mortality. 
Cinaciguat is a novel sGC activator that binds to the NO-sensitive oxidized ferric (Fe3+) or 
heme-free sGC, thus stimulating cGMP synthesis. In this way, the substance is effective 
under oxidative stress, which is present in many cardiovascular diseases. 
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Despite limited clinical data for cinaciguat, preliminary studies in patients with ADHF 
demonstrate a significant hemodynamic benefit and reduction of symptoms. Further studies 
are required to evaluate cinaciguat, in particular, because of its novel and promising mode 
of action. There is a need for studies that address long-term symptoms and mortality in a 
larger number of patients with ADHF. 
Riociguat (BAY 63-2521) has been investigated in 14 clinical pharmacological studies 
confirming the mechanism of action of the compound as an sGC stimulator. 
A proof-of-concept study in patients with pulmonary hypertension showed that sGC 
stimulation exerted by a single dose of riociguat had the expected favorable hemodynamic 
effects on subjects with pulmonary hypertension. 
In a phase 2 study, riociguat, at doses between 1 mg three times daily and 2.5 mg three times 
daily, was administered for 12 weeks to 72 subjects with pulmonary arterial hypertension 
and chronic thromboembolic pulmonary hypertension. 
Riociguat was generally safe and well tolerated and exerted significant and favorable effects 
on pulmonary hemodynamics and functional capacity. This was supported by evidence 
from echocardiography biomarker and functional class assessment. 
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